Natus Medical Incorporated

NasdaqGS:NTUS Stock Report

Market Cap: US$1.1b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Natus Medical Future Growth

Future criteria checks 3/6

Key information

58.9%

Earnings growth rate

58.1%

EPS growth rate

Medical Equipment earnings growth16.1%
Revenue growth rate4.4%
Future return on equityn/a
Analyst coverage

Low

Last updatedn/a

Recent future growth updates

Breakeven Is Near for Natus Medical Incorporated (NASDAQ:NTUS)

May 05
Breakeven Is Near for Natus Medical Incorporated (NASDAQ:NTUS)

Breakeven Is Near for Natus Medical Incorporated (NASDAQ:NTUS)

Jan 11
Breakeven Is Near for Natus Medical Incorporated (NASDAQ:NTUS)

Recent updates

Novanta to replace Six Flags Entertainment in S&P MidCap 400, Six Flags to replace Natus Medical in S&P SmallCap 600

Jul 22

Some Investors May Be Worried About Natus Medical's (NASDAQ:NTUS) Returns On Capital

Mar 04
Some Investors May Be Worried About Natus Medical's (NASDAQ:NTUS) Returns On Capital

Some Investors May Be Worried About Natus Medical's (NASDAQ:NTUS) Returns On Capital

Nov 08
Some Investors May Be Worried About Natus Medical's (NASDAQ:NTUS) Returns On Capital

We Like Natus Medical's (NASDAQ:NTUS) Earnings For More Than Just Statutory Profit

Aug 13
We Like Natus Medical's (NASDAQ:NTUS) Earnings For More Than Just Statutory Profit

Does Natus Medical (NASDAQ:NTUS) Have A Healthy Balance Sheet?

Aug 02
Does Natus Medical (NASDAQ:NTUS) Have A Healthy Balance Sheet?

We Think Shareholders Are Less Likely To Approve A Pay Rise For Natus Medical Incorporated's (NASDAQ:NTUS) CEO For Now

Jun 10
We Think Shareholders Are Less Likely To Approve A Pay Rise For Natus Medical Incorporated's (NASDAQ:NTUS) CEO For Now

Breakeven Is Near for Natus Medical Incorporated (NASDAQ:NTUS)

May 05
Breakeven Is Near for Natus Medical Incorporated (NASDAQ:NTUS)

Is Natus Medical (NASDAQ:NTUS) Using Debt Sensibly?

Feb 15
Is Natus Medical (NASDAQ:NTUS) Using Debt Sensibly?

Breakeven Is Near for Natus Medical Incorporated (NASDAQ:NTUS)

Jan 11
Breakeven Is Near for Natus Medical Incorporated (NASDAQ:NTUS)

Reflecting on Natus Medical's (NASDAQ:NTUS) Share Price Returns Over The Last Five Years

Dec 07
Reflecting on Natus Medical's (NASDAQ:NTUS) Share Price Returns Over The Last Five Years

Earnings and Revenue Growth Forecasts

NasdaqGS:NTUS - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202351745N/AN/A1
12/31/202249534N/AN/A1
3/31/2022478134448N/A
12/31/2021473136064N/A
9/30/2021464176569N/A
6/30/202145226569N/A
3/31/2021421-113642N/A
12/31/2020416-172634N/A
9/30/2020428-192029N/A
6/30/2020449-13646N/A
3/31/2020490116471N/A
12/31/2019495-165560N/A
9/30/2019505-305562N/A
6/30/2019512-443846N/A
3/31/2019517-502533N/A
12/31/2018531-232433N/A
9/30/2018521-181724N/A
6/30/2018513-211421N/A
3/31/2018505-241925N/A
12/31/2017501-201620N/A
9/30/2017477-31518N/A
6/30/2017445194750N/A
3/31/2017419345255N/A
12/31/2016382436973N/A
9/30/2016374416770N/A
6/30/2016378394650N/A
3/31/2016374383742N/A
12/31/201537638N/A37N/A
9/30/201537040N/A44N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NTUS's forecast earnings growth (58.9% per year) is above the savings rate (1.9%).

Earnings vs Market: NTUS's earnings (58.9% per year) are forecast to grow faster than the US market (13.1% per year).

High Growth Earnings: NTUS's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: NTUS's revenue (4.4% per year) is forecast to grow slower than the US market (8% per year).

High Growth Revenue: NTUS's revenue (4.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if NTUS's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.